Literature DB >> 3691612

A theophylline dosage regimen which reduces round-the-clock variations in plasma concentrations resulting from diurnal pharmacokinetic variation.

M B Regazzi1, R Rondanelli, E Vida, F Farinelli, R A Upton.   

Abstract

Slower drug absorption at night can leave residual drug from an evening dose of a sustained-release product remaining to be absorbed at the time of the next morning's dose, thereby giving higher plasma concentrations of the drug during the day than the night. When a capsule product releasing theophylline over 12 h after a morning dose was given repetitively at 8 a.m. and 8 p.m. for 4 days, daytime plasma concentrations from 4 h to 8 h after the dose were about 40% greater than corresponding night-time concentrations, and the mean steady-state concentration during the night-time interval was only 81% of that during the daytime interval. Altering the regimen to one capsule at 12 noon and one at 10 p.m. eliminated all significant differences between a.m. and corresponding p.m. plasma concentrations of theophylline and between the mean steady-state concentrations for each of the interdose intervals within a day.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691612     DOI: 10.1007/bf00637556

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Diurnal variation in the pharmacokinetics of intravenous theophylline and etophylline in healthy subjects.

Authors:  B L Chauhan; B S Doshi; R D Kulkarni
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Desynchronization and resynchronization of human circadian rhythms.

Authors:  J Aschoff
Journal:  Aerosp Med       Date:  1969-08

3.  Nocturnal theophylline plasma concentrations.

Authors:  J H Jonkman; W J van der Boon
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

4.  Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics.

Authors:  P H Scott; E Tabachnik; S MacLeod; J Correia; C Newth; H Levison
Journal:  J Pediatr       Date:  1981-09       Impact factor: 4.406

5.  Temporal variations in trough serum theophylline concentrations at steady state.

Authors:  L J Lesko; D Brousseau; A T Canada; G Eastwood
Journal:  J Pharm Sci       Date:  1980-03       Impact factor: 3.534

6.  Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24.

Authors:  M M Weinberger
Journal:  Pharmacotherapy       Date:  1984 Jul-Aug       Impact factor: 4.705

7.  Temporal variation in the disposition of theophylline and its metabolites.

Authors:  M V St-Pierre; M Spino; A F Isles; A Tesoro; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

  7 in total
  2 in total

Review 1.  Chronopharmacology and its application to the development of theophylline treatment schedules for asthma.

Authors:  K R Godfrey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.

Authors:  A Fujimura; Y Kumagai; K Sugimoto; H Nakashima; H Kajiyama; A Ebihara; K Ohashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.